Hyperglycemia is a crucial factor in the development of diabetic nephropathy. We previously showed that high glucose upregulates thrombospondin 1 (TSP1)-dependent transforming growth factor (TGF)-␤ activation by altering cGMP-dependent protein kinase (PKG) activity as a result of decreased nitric oxide signaling. In the present study, we showed that high glucose concentrations significantly reduced endogenous PKG activity. To further examine the mechanisms by which PKG regulates TSP1 expression and TSP1-dependent TGF-␤ activation, we generated stably transfected rat mesangial cells (RMCs) with inducible expression tetracyclineinduced gene expression of the catalytic domain of PKG. After tetracycline induction, the catalytic domain of PKG is expressed as a cGMP-independent active kinase. Expression of the catalytic domain prevented high glucose-mediated increases in transcription of the TSP1 gene with no alteration in TSP1 mRNA stability. Glucose stimulation of TSP1 protein expression and TGF-␤ bioactivity were also downregulated. TGF-␤-dependent fibronectin and type IV collagen expression under high glucose conditions were significantly reduced upon catalytic domain expression in transfected RMCs. These results show that constitutively active PKG inhibits the fibrogenic potential of high glucose through repression of TSP1-dependent TGF-␤ bioactivity, suggesting that gene transfer of the catalytic domain of PKG might provide a new strategy for treatment of diabetic renal fibrosis.
T hrombospondin 1 (TSP1), a disulfide-linked 180-kDa trimer, is a multifunctional protein that is produced by a variety of cells, including mesangial cells (1) , and can be regulated by many factors (2-7). TSP1 is a major physiological regulator of transforming growth factor (TGF)-␤ activation (8 -10) . Our earlier work showed that TSP1 is also responsible for the activation of TGF-␤ in mesangial cells exposed to high concentrations of glucose, which contributes to the accumulation of extracellular matrix proteins (11) . Furthermore, high glucose mediates increases in TSP1 expression and TSP1-dependent TGF-␤ bioactivity through downmodulation of cGMP-dependent protein kinase (PKG) signaling (12) . However, the mechanism by which PKG regulates TSP1 expression and TGF-␤ bioactivity in the presence of high glucose has not been previously determined.
PKG is a serine/threonine kinase consisting of a regulatory and a catalytic domain within one polypeptide chain (13) . The COOH-terminal catalytic domain contains an ATP-binding pocket and an activating phosphorylation site. The activating phosphorylation site provides recognition sites for protein/peptide substrate binding and catalysis, which is directly relevant to PKG activity. The aminoterminal regulatory domain consists of a leucine/isoleucine zipper motif (an autophosphorylation/autoinhibitory region) and two homologous cyclic nucleotide binding domains. Binding of cGMP by the regulatory domain leads to activation of the catalytic domain (14) . In mammalian cells, two genes encoding PKG have been identified, type I and type II (15) . Consistent with a previous report (16) , we showed by immunoblotting that type I is the only PKG expressed rat mesangial cell (RMC). Our previous studies showed that high glucose concentrations downregulate PKG as a result of diminished nitric oxide (NO)-dependent generation of cGMP (12) .
PKG regulates gene expression at both transcriptional and posttranscriptional levels. It increases gene expression of some proteins (c-fos, junB, and mitogen-activated protein kinase phosphatase I) and decreases expression of others (gonadotropin-releasing hormones, soluble guanylate cyclase, and TSP1) (17) (18) (19) . Activation of the cAMP response, serum response, activator protein-1 (AP-1) elements, and transcriptional regulator TFII-I are reported to be involved in PKG-regulated gene transcription (20 -23) . However, the mechanism by which PKG represses TSP1 gene expression is unknown.
In the present study, we generated stably transfected RMCs with tetracycline-regulated expression of the catalytic domain of PKG-I. PKG-I is alternately spliced at the first exon to encode two isoforms: PKG-I␣ and PKG-I␤. These enzymes differ only in the amino-terminal domain (through residues 89 and 104, respectively) and therefore contain identical catalytic domains (15, 24) . The catalytic domain of PKG has been expressed in a baculovirus system and in transfected rat aorta smooth muscle cells, resulting in a constitutively active kinase, independent of cGMP activation (25) . This provides a system to define the role of PKG activity in cells, independent of upstream signaling (e.g., NO or cGMP).
Data from our studies show that expression of the catalytic domain of PKG significantly represses TSP1 gene expression under high glucose conditions. Regulation occurs at the level of transcription. TSP1-dependent TGF-␤ bioactivity and excessive extracellular matrix (ECM) synthesis are also inhibited under high glucose conditions by the expression of catalytic domain. These results indicate that PKG activity plays a role in glucose-mediated TSP1-dependent TGF-␤ activation and resultant ECM production.
international units/ml insulin. Serum-free RPMI-1640 media were used to quiescent RMCs. Transfection was carried out by using Effectene as described by the manufacturer. RMCs (50 -70% confluent) were transfected with 0.8 g pcDNA 6/TR (Invitrogen) for 18 h in RPMI-1640 media containing 20% FBS and selected with 3 g/ml blasticidin. Once a stable cell line expressing the tetrocycline repressor (TetR) was obtained, these cells were cotransfected with 0.8 g pcDNA4/TO/myc-His C/CD (a construct of the catalytic domain of G-kinase I ␣ (bp 999-2016) or empty vector (pcDNA4/TO/myc-His C) as control cells. Stably transfected cells (labeled as RMC [tr/cd]) were selected with 3 g/ml blasticidin and 500 g/ml zeocin.
Detection of catalytic domain of PKG transgene expression
Immunoblotting. RMCs (tr/cd) were made quiescent in serum-free RPMI-1640 media with tetracycline (0.2-1.5 g/ml) for 2 days and then were harvested in cold PEM buffer (20 mmol/l sodium phosphate [pH 6.8], 2 mmol/l EDTA,15 mmol/l ␤-mercaptoethanol, 0.15 mol/l NaCl, 0.1 mmol/l phenylmethysulfonyl fluoride, 10 g/ml leupeptin, 10 g/ml pepstatin A, and 5 g/ml aprotinin) and homogenized (25) . The extract was subjected to 10% SDS-PAGE and transferred to polyvinylidine fluoride membrane to detect catalytic domain of PKG by using polyclonal anti-PKG antibody. RT-PCR. Total RNA was extracted from RMCs and RMC (tr/cd). RNA (1 g) was subjected to one-step RT-PCR (Invitrogen). Primers and conditions for amplification of the catalytic domain of PKG I genes were described previously (25) . PKG enzyme activity assay. To assess the biological activity of the expressed catalytic domain of PKG, PKG enzyme activity was measured in RMC (tr/cd) using methods described previously (24) . PKG enzyme activity is expressed as nanomoles of peptide phosphorylated per minute per milligram of cell extract protein.
Western blotting. Cells were cultured and made quiescent for 48 h in the presence of 1 g/ml tetracycline and then treated for the next 24 h with serum-free RPMI-1640 media containing either 5 or 30 mmol/l glucose. Conditioned media were harvested, and equal amounts of protein were subjected to SDS-PAGE gel (8%) under reducing conditions for detecting TSP1 and fibronectin. For detection of type IV collagen, cells were harvested in Laemmli sample buffer. After electrophoretic transfer to nitrocellulose membranes and blocking, the membranes were incubated with mouse monoclonal anti-TSP1 antibody 133 (1:5,000), rabbit anti-rat fibronectin antibody (1:1,000), or rabbit anti-type IV collagen antibody (1:5,000) for 1 h at room temperature. After washing, secondary antibody was used for the detection of immunoreactive bands with enhanced chemiluminescence detection system. Transfection and luciferase assay. Cells were transiently transfected using Effectene with (0.3 g) luciferase reporter plasmid containing the Ϫ2,033/ ϩ750 region of the human TSP1 gene promoter (a gift from Dr. Paul Bornstein, University of Washington). Luciferase activities were assayed 24 h posttransfection using the dual luciferase assay kit (Promega) according to the manufacturer's directions. TGF-␤ assay. Total and active TGF-␤ levels in the condition media were assayed using the plasminogen activator inhibitor-1 (PAI-1)/luciferase assay as described previously (12, 27) . The standard curve was obtained by using human recombinant TGF-␤1 (R&D Systems), which was not affected by high glucose concentrations (30 mmo/l glucose). Measurement of TSP1 mRNA stability. RMC (tr/cd) were made quiescent in the absence or presence of tetracycline for 48 h and then treated with 30 mmol/l glucose for 24 h. After 24 h, media were removed and actinomycin D was added (designated as t ϭ 0). After additional time points, cells were harvested. Northern analysis and hybridization for TSP1 and GAPDH were performed as described previously (12) . Measurement of the ratio of TSP1/ GAPDH at t ϭ 0 (from actinomycin D treatment) was assigned a relative value of 100%. Statistical analysis. Data are expressed as the mean Ϯ SD. Statistical evaluation of the data was performed using the Student's t test, considering a P value of Ͻ0.05 as significant.
RESULTS AND DISCUSSION
Establishment of stably catalytic domain of PKGtransfected RMCs (tr/cd) with an inducible expression system (tetracycline-induced gene expression). We previously showed that high concentrations of glucose mediate increases in TSP1 expression and TSP1-dependent TGF-␤ bioactivity through down-modulation of NOdependent PKG signaling (12) . To directly investigate the role of PKG in regulation of TSP1 expression, we generated stable transfectants expressing the catalytic domain of PKG in RMCs (tr/cd) using an inducible expression system (tetracycline-induced gene expression [Tet-On]). Catalytic domain expression was determined in the cell lysate after 48 h in the presence of 0 -1.5 g/ml tetracycline (Fig. 1A) . Induction of catalytic domain expression was time-dependent and sustained for at least 72 h (Fig.  1B) . The RT-PCR results further confirmed the expression of a 1,000-bp band corresponding to the catalytic domain of PKG in RMCs (tr/cd) (Fig. 1C) . Activity of the catalytic domain was assessed using a selective PKG substrate, the BPDEtide (24). Cells were assayed in the presence or absence of cGMP to distinguish endogenous PKG activity from that of the cGMP-independent catalytic domain. As shown in Table 1 , basal PKG activity was ϳ4.5 nmol, and activity approximately doubled in the presence of cGMP. There was no difference in basal PKG activity between control cells and RMCs (tr/cd) without tetracycline induction. After 1 g/ml tetracycline induction, PKG activity in RMCs (tr/cd) increased ϳ2.8-fold compared with RMCs (tr/cd) without tetracycline induction. Moreover, addition of cGMP further increased PKG activity in RMCs (tr/cd) due to the activation of endogenous PKG by cGMP. These results indicate that the PKG catalytic domain expressed in RMCs (tr/cd) is fully active. This Tet-On system allows us to directly regulate the activity of PKG independent of cGMP levels and enables us to investigate the effects of PKG on glucosemediated TSP1 gene expression, TGF-␤ bioactivity, and concomitant ECM expression. Effects of high glucose on PKG activity and TSP1 gene expression in stably transfected cells. Previously, we showed that high glucose inhibits NO production and intracellular cGMP levels. However, PKG protein levels were not altered (12) . To determine the effects of high glucose on PKG activity, RMCs (tr/cd) were cultured in the presence of tetracycline (0 -1.5 g/ml) and then treated with high concentrations of glucose. Cell lysates were analyzed for PKG activity. As shown in Fig. 2A , high glucose concentrations significantly decreased endogenous PKG activity (tet ϭ 0) (P Ͻ 0.001). The endogenous PKG activity in media with 30 mmol/l glucose is only 10% of that in 5 mmol/l glucose media. However, with the addition of cGMP (10 mol/l), the endogenous PKG activity was essentially equivalent in cells exposed to either 5 or 30 mmol/l glucose, suggesting that the glucose-mediated decrease in intracellular cGMP levels is responsible for the reduced endogenous PKG activity (12) . To the best of our knowledge, this is the first direct evidence that glucose downregulates PKG activity.
Furthermore, PKG activity was also measured upon tetracycline induction of RMCs (tr/cd). In the absence of added cGMP, 1 and 1.5 g/ml tetracycline induced sufficient PKG activity to overcome glucose-mediated downregulation of PKG activity. Expression of the PKG catalytic domain and addition of cGMP to activate endogenous PKG resulted in similar levels of PKG activity under both 5 and 30 mmol/l glucose conditions ( Fig. 2A) . High concentrations of glucose did not change the expression of the catalytic domain compared with normal glucose (data not shown).
Consistent with these observations, glucose stimulation of TSP1 mRNA (Fig. 2B, 2C ) and protein levels ( Fig. 2D and E) decreased to basal levels (under 5 mmol/l glucose conditions) with tetracycline (1 and 1.5 g/ml) induction. In addition, high glucose-mediated upregulation of TSP1 expression is TGF-␤ independent, since anti-TGF-␤ antibody could not alter TSP1 protein expression (Fig. 2F) . Taken together, these data suggest that expression of the PKG catalytic domain to restore PKG activity independent of cGMP levels overcomes high glucose stimulation of TSP1 gene expression. Expression of catalytic domain of PKG reduces high glucose stimulation of TSP1-dependent TGF-␤ activity. TSP1 has been shown to be a major physiological regulator of TGF-␤ activation. Previously, we have demonstrated that increased TSP1 expression is responsible for high glucose stimulation of TGF-␤ bioactivity (9 -11) . Furthermore, downregulation of NO-dependent PKG activation was responsible for glucose stimulation of TSP1 protein and TSP1-dependent TGF-␤ activation (12) . Therefore we examined whether stimulation of PKG activity would block these increases in TGF-␤ activity. As shown in Fig. 3A , after tetracycline induction in RMCs (tr/cd) the elevated level of TGF-␤ bioactivity under high glucose conditions was reduced to basal levels. Moreover, exogenously added sTSP1 (2 or 10 nmol/l) overcame the actions of PKG in regulating TGF-␤ activity, suggesting that the effect of PKG on regulation of TGF-␤ activity occurs as a result of down regulation of TSP1 expression. Total TGF-␤ levels were not affected by either increased PKG activity or exogenously added sTSP1 (Fig. 3B) . In the absence of tetracycline, treatment of the cells with sTSP1 resulted in a similar fold increase in active TGF-␤ levels under either normal or high glucose conditions. No significant changes were observed in the levels of total TGF-␤ with various doses of sTSP1 treatment (data not shown).
The specificity of the luciferase response for TGF-␤ signaling in PAI-1/luciferse assay was previously tested by using an anti-TGF-␤ antibody. The antibody to TGF-␤ nearly completely blocked the luciferase reporter activity in those assays. In addition, results were also confirmed by using the R&D systems Quantikine enzyme-linked immunosorbent assay for TGF-␤1 (12).
Expression of catalytic domain of PKG inhibits fibronectin and collagen production under high glucose concentrations. TGF-␤ has been shown to stimulate ECM production under high glucose conditions, which play an important role in the development of diabetic nephropathy (28 -29) . Our lab has demonstrated that high glucose stimulation of ECM protein expression in mesangial cells is dependent on TSP1-mediated activation of TGF-␤ (11). Without tetracycline induction, high glucose stimulated fibronectin and type IV collagen production in RMCs (tr/cd). These effects of glucose are TGF-␤ dependent because fibronectin and type IV collagen upregulation by high glucose could be blocked by anti-TGF-␤ neutralizing antibody. In RMCs (tr/cd) with tetracycline induc- tion, increased PKG activity inhibited high glucosemediated increases in fibronectin and type IV collagen protein levels (Fig. 4) . Expression of catalytic domain of PKG represses glucose simulation of TSP1 expression at transcriptional level. Our data show that PKG regulates both TSP1 mRNA and protein levels. To better understand how PKG regulates transcription, we examined steady-state TSP1 mRNA levels. As shown in Fig. 5A and B, in control cells high glucose increased TSP1 mRNA levels in a timedependent manner with a fourfold increase at 24 h as compared with normal glucose. In RMCs (tr/cd) without tetracycline induction, high glucose similarly increased TSP1 mRNA levels ( Fig. 5C and D) . However, with tetracycline induction of PKG activity, glucose stimulation failed to upregulate TSP1 mRNA.
TSP1 mRNA stability was unaffected with expression of the catalytic domain (Fig. 6) . Consistent with the report of Donoviel et al. (30) , TSP1 mRNA was degraded with a half-life of ϳ5.5 h. Our data suggest that increased PKG activity does not alter the rate of TSP1 mRNA turnover.
Alternately, PKG might affect the transcriptional activity of the TSP1 promoter. The TSP1 gene promoter region has been characterized (31) (32) . With the transfection of a full-length human TSP1 gene promoter-reporter construct (Ϫ2,033 to ϩ750) into RMCs (tr/cd), we found that increased PKG activity inhibited high glucose-stimulated reporter activity (Fig. 7) . Anti-TGF-␤ antibody had no effect on reporter activity, suggesting that the effect of PKG on TSP1 transcription is TGF-␤ independent, consistent with our previous observations (11, 12) . Furthermore, region Ϫ1,172 to Ϫ548 of the human TSP1 promoter, containing binding sites for transcription factors such as AP-1, Sp-1, SRF, and upstream stimulatory factor (USF), is involved in transcriptional repression by PKG (data not shown). Recently, Volpert et al. (33) showed that Id1 represses TSP1 promoter activity in mouse embryo fibroblasts, and a strong repressive region in Ϫ1,120 to Ϫ1,310 of the murine TSP1 promoter was identified. This transcriptional repression region overlaps with part of the PKG repressive region in the TSP1 promoter, suggesting that Id might be involved in the mechanisms by which PKG represses TSP1 gene transcription. Id, expressed in mesangial cells (34) , is a family of dominant-negative helixloop-helix (HLH) proteins that block cell-specific transcription mediated by basic HLH transcription factors (36) . USF, a member of the basic HLH leucine zipper family (37) , has been shown to be a glucose-responsive transcription factor (38) . Glucose-induced expression of Id1 (35) might bind to USF, leading to PKG-mediated repression of TSP1 gene transcription under high glucose conditions. Such a mechanism would be consistent with the lack of PKG regulation of basal TSP1 gene transcription observed in previous studies (39) in which basal TSP1 mRNA levels only slightly decreased in aortic smooth muscle cells 48 h after transfection with the constitutively active catalytic domain of PKG-I. Under basal conditions, posttranscriptional mechanisms appear to be involved. The roles of PKG in modulating transcription factors that regulate TSP1 promoter are currently under investigation.
In summary, our data show that increased PKG activity abolished glucose stimulation of TSP1-dependent TGF-␤ bioactivity, resulting in decreased ECM protein levels. These data suggest that PKG-regulated TSP1-dependent TGF-␤ activity plays a role in the pathogenesis of diabetic nephropathy. Gene transfer of the catalytic domain of PKG to modulate PKG activity might provide new strategies for the treatment of diabetic renal fibrosis.
